University of Colorado researchers found that arise from stem cells of muscle invasion and another muscle-invasive bladder cancer

Published today in the journal stem cells University of Colorado Cancer Center Research create a dangerous, invasive bladder cancer precursor cells shows that muscle with non-invasive bladder cancer to create progenitor cells.

View the original article here

Researchers find potential new treatment approach for pancreatic cancer

Dec. 20, 2013 — Scientists from The University of Manchester -- part of Manchester Cancer Research Centre believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients.

Pancreatic cancer is an aggressive cancer with poor prognosis and limited treatment options and is highly resistant to chemotherapy and radiotherapy.

But researchers believe they have found an effective strategy for selectively killing pancreatic cancer while sparing healthy cells which could make treatment more effective.

Dr Jason Bruce, from the Physiological Systems and Disease Research Group, who led the research, said: "Pancreatic cancer is one of the most aggressive and deadly cancers. Most patients develop symptoms after the tumour has spread to other organs. To make things worse, pancreatic cancer is highly resistant to chemotherapy and radiotherapy. Clearly a radical new approach to treatment is urgently required. We wanted to understand how the switch in energy supply in cancer cells might help them survive."

The research, published in The Journal of Biological Chemistry this month, found pancreatic cancer cells may have their own specialised energy supply that maintains calcium levels and keeps cancer cells alive.

Maintaining a low concentration of calcium within cells is vital to their survival and this is achieved by calcium pumps on the plasma membrane.

This calcium pump, known as PMCA, is fuelled using ATP -- the key energy currency for many cellular processes.

All cells generate energy from nutrients using two major biochemical energy "factories," mitochondria and glycolysis. Mitochondria generate approximately 90% of the cells' energy in normal healthy cells. However, in pancreatic cancer cells there is a shift towards glycolysis as the major energy source. It is thought that the calcium pump may have its own supply of glycolytic ATP, and it is this fuel supply that gives cancer cells a survival advantage over normal cells.

Scientists used cells taken from human tumours and looked at the effect of blocking each of these two energy sources in turn.

Their study, funded by the Biotechnology and Biological Sciences Research Council (BBSRC), National Institute of Health Research (NIHR) Biomedical Research Centre and AstraZeneca, shows that blocking mitochondrial metabolism had no effect. However, when they blocked glycolysis, they saw a reduced supply of ATP which inhibited the calcium pump, resulting in a toxic calcium overload and ultimately cell death.

Dr Bruce added: "It looks like glycolysis is the key process in providing ATP fuel for the calcium pump in pancreatic cancer cells. Although an important strategy for cell survival, it may also be their major weakness.

"Designing drugs to cut off this supply to the calcium pumps might be an effective strategy for selectively killing cancer cells while sparing normal cells within the pancreas."

Maggie Blanks, CEO of the national charity, the Pancreatic Cancer Research Fund said: "These findings will certainly of great interest to the pancreatic cancer research community and we'd be keen to see how this approach progresses. Finding weaknesses that can be exploited in this highly aggressive cancer is paramount, so we want to congratulate the Manchester team for their discovery."

View the original article here

Translate the new findings to enhance treatment of patients with malignant melanoma cancer researchers.

From translational researchers at UCLA's Jonsson Comprehensive Cancer Center (number of days), published results of a study provide insightful journal Cancer found BRAF inhibitor resistance two key areas critical to tumor how two back-to-back: focus and use to learn how to be resistant to melanoma tumor cells inhibitor with cell signal transduction pathway BRAF-mutant, evolve and limited development cell BRAF inhibitor drug resistance is how black keys.

View the original article here

Work the researchers to improve the outcomes of patients with lymphoma.

University of Nebraska Medical Center （ Fred & Pamela Buffett cancer center headquartered ） of researchers are diffuse large B cell lymphoma patient they discovered that do not respond to standard drug therapy used to treat this type of cancer if you have a high level of gene called STAT3. Findings will be published in medical journal 11 issue of the journal Clinical Oncology, Clinical Oncology, American society.

View the original article here

Researchers identify biomarkers for lung cancer in smokers.

Succeeded to identify smoking-related lung cancer has a pair of specific proteins of prognostic markers Mayo Clinic researchers have shown. Protein — ASCL1 — is associated with increased expression of RET gene, called the RET of certain cancer-causing gene. The findings appear in the online issue of the journal genes.

View the original article here

Researchers discover a new way that influenza can infect cells

Sep. 23, 2013 — Scientists at Fred Hutchinson Cancer Research Center have uncovered a new mechanism by which influenza can infect cells -- a finding that ultimately may have implications for immunity against the flu.

Influenza viruses have two main proteins on their surface that allow them to do their dirty work: a protein called hemagglutinin allows viruses to infect cells, while a protein called neuraminidase allows viruses to escape from cells.

Now in a paper published online ahead of the December print issue of the Journal of Virology, Jesse Bloom, Ph.D., an evolutionary biologist and assistant member of the Fred Hutch Basic Sciences Division, and Kathryn Hooper, a graduate research assistant in the Bloom Lab, describe the discovery of an influenza virus that instead uses neuraminidase to attach to cells.

The researchers discovered the new mechanism of infection after mutating the hemagglutinin of a lab-adapted strain of influenza so that it could no longer attach to cells.

"We expected that viruses with the mutated hemagglutinin wouldn't be able to infect cells," said Bloom, who also is a computational biologist and an assistant member of the Fred Hutch Public Health Sciences Division. "So we were surprised when a virus with this hemagglutinin started to grow. We were even more surprised when we sequenced the virus and discovered that it had evolved a mutation in neuraminidase."

Hooper began characterizing the new virus in detail. She discovered that the mutation allowed neuraminidase to attach the virus to cells. Hemagglutinin's ability to bind to cells -- long considered one of the protein's most crucial and conserved properties -- was no longer necessary for infection.

What does this finding mean for influenza in humans? That remains an open question, but Bloom and Hooper have already shown that the neuraminidase mutation they discovered is present in some human isolates of influenza.

"This was not a mutation we expected to find in the lab, let alone in viruses that have infected humans over the past few years," Hooper said. "It suggests there is influenza circulating in nature that may be infecting cells by a mechanism that has been overlooked by others in the field."

The researchers are now carefully characterizing human influenza isolates that have the mutation. They are also looking for other mutations that allow neuraminidase to attach viruses to cells.

They say there is a possibility that these types of mutations may have implications for immunity against influenza, since they might enable the virus to escape from antibodies that block the binding of hemagglutinin to cells.

View the original article here

Washington U researchers have developed a new model of drug resistance in breast cancer treatment tips for better.

May be researchers in medicine, Washington University in St. Louis were transplanted into human breast cancer tumors are a valuable tool in search models of metastatic carcinoma of superior and better treatments are shown.

View the original article here

Researchers identify switch that controls growth of most aggressive brain tumor cells

Sep. 20, 2013 — Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and aggressive malignant brain tumor.

Findings of their investigation show that the protein RIP1 acts as a mediator of brain tumor cell survival, either protecting or destroying cells. Researchers believe that the protein, found in most glioblastomas, can be targeted to develop a drug treatment for these highly malignant brain tumors. The study was published online Aug. 22 in Cell Reports.

"Our study identifies a new mechanism involving RIP1that regulates cell division and death in glioblastomas," said senior author Dr. Amyn Habib, associate professor of neurology and neurotherapeutics at UT Southwestern, and staff neurologist at VA North Texas Health Care System. "For individuals with glioblastomas, this finding identified a target for the development of a drug treatment option that currently does not exist."

In the study, researchers used animal models to examine the interactions of the cell receptor EGFRvIII and RIP1. Both are used to activate NFκB, a family of proteins that is important to the growth of cancerous tumor cells. When RIP1 is switched off in the experimental model, NFκB and the signaling that promotes tumor growth is also inhibited. Furthermore, the findings show that RIP1 can be activated to divert cancer cells into a death mode so that they self-destruct.

According to the American Cancer Society, about 30 percent of brain tumors are gliomas, a fast-growing, treatment-resistant type of tumor that includes glioblastomas, astrocytomas, oligodendrogliomas, and ependymomas. In many cases, survival is tied to novel clinical trial treatments and research that will lead to drug development.

View the original article here

Heart Infection Causing Fewer Hospitalizations, Researchers Say

THURSDAY, Sept. 19 (HealthDay News) -- Hospitalizations for a deadly heart infection that affects mainly older people have declined in recent years, a new study finds. This was seen even with recommendations for more limited use of antibiotics to prevent the illness, called endocarditis.

Specifically, endocarditis is inflammation of the inside living of the heart valve and chambers, according to the U.S. National Heart, Lung, and Blood Institute. The risk of endocarditis increases when people have surgery, and it's considered the most serious infection of the cardiovascular system.

There was a significant increase in rates of hospitalization for endocarditis in the 1990s, which led many doctors to prescribe antibiotics before dental procedures and certain types of surgery.

However, the American Heart Association has narrowed the recommended use of antibiotics to prevent endocarditis to only a subgroup of patients undergoing dental procedures.

In this study, Yale School of Medicine researchers looked at the annual rates of endocarditis-related hospitalizations and related outcomes among more than 262,000 Medicare patients 65 and older between 1999 and 2010.

An increase in hospitalizations for endocarditis occurred between 1999 and 2005, but there was a decline between 2006 and 2010, according to the study in the August Journal of the American College of Cardiology.

"We were surprised to see reduced rates of endocarditis hospitalizations during this time period," study first author Dr. Behnood Bikdeli, a postdoctoral associate in cardiovascular medicine, and an internal medicine resident, said in a Yale news release.

"This downward trend was consistent in all major study subgroups, but certain subgroups, including black participants, had higher hospitalization rates and worse outcomes in the study period," he added.

This racial disparity in outcomes, as well as reasons for the overall decline in hospitalizations, require further investigation, Bikdeli said.

"Clinicians should consider the risks and benefits of antibiotic use on a case-by-case basis and should share the information with their patients for appropriate decision making," he concluded.

More information

The U.S. National Heart, Lung, and Blood Institute has more about endocarditis.

Copyright c 2013?HealthDay. All rights reserved.

View the original article here

Identify new targets for treatment of Sanford-Burnham researchers malignant melanoma.

Sanford Burnham Medical Research Institute, scientists announced discovery of an important role in the progression of the play development of genes, enzymes, and inositol phosphorus lipid dependent kinase 1 （ PDK1) and malignant melanoma. It offers new approach to disease treatment available in an advanced online publication gene finding with this life-threatening.

View the original article here

Identifies the mechanisms to supervise development professional Oncology network of researchers.

Roswell Park cancer researchers of the Institute (RPCI) will stimulate interfere with antitumor response discovered a new pathway in breast cancer how cancer cells, bone marrow-derived suppressor cells (MDSCs) expansion of known blood cell population. Survey results will be published online today in the journal of clinical investigation may shed new light on that fuel tumor growth of pathological events, it will lead to development of new distractions.

View the original article here

Researchers study ways to make stronger materials in 3-D

Sep. 17, 2013 — Aided by funding from NASA and using methods similar to 3-D printing, researchers at Missouri University of Science and Technology are running computer simulations of processes that could lead to stronger, more durable materials for the space agency.

The Missouri S&T researchers also plan to fabricate some of these new materials soon, says Dr. Frank Liou, director of the university's Laser Aided Manufacturing Process (LAMP) Laboratory and the Michael and Joyce Bytnar Professor of Product Innovation and Creativity.

For the past 15 years, Liou and his colleagues have been developing a fabrication method known as additive manufacturing. The process involves the use of high-powered lasers to melt small particles of powdered materials as they exit a nozzle to create three-dimensional shapes, layer by layer. The technique is similar to 3-D printing, which has grown in popularity in recent years.

According to Liou, the additive approach applies to a broad range of manufacturing -- from the fabrication of large aircraft components to minuscule biomaterials used in surgical procedures. Some of Liou's students who enjoy fishing even joke about using LAMP's additive manufacturing tools to make a canoe, layer by layer.

Additive manufacturing approaches result in a denser, stronger material than conventional methods, such as milling, machining or forging of metals. Liou, who also directs Missouri S&T's manufacturing engineering program, says steel parts made using the additive method are 10 percent stronger than steel that is machined.

In his latest research, Liou is combining additive manufacturing with more conventional approaches to creating materials. He calls the approach "hybrid manufacturing."

With hybrid manufacturing, S&T researchers could apply an additive manufacturing technique to create aircraft components from two different metals -- perhaps steel and copper -- and then smooth the parts' rough edges using automated computer-numerical control machining.

Liou has received about $660,000 from NASA to develop computer models of various additive manufacturing approaches. He believes the models will lead to a greater understanding of how layered materials adhere, or bond, to the surface on which they are deposited.

"In many aerospace or biomedical applications, you cannot afford metal fatigue," or cracking of the material, Liou says. "It is important to understand how well a deposited metal bonds to the surface."

Liou recently received another $750,000 from NASA to support the next step of this research: the fabrication of new materials not generally observed in nature. The research could lead to stronger metals as well as a way to repair expensive components instead of scrapping them, Liou says.

"Some dies or molds could cost a quarter of a million dollars to replace," Liou says.

View the original article here

University of Southern California researchers find molecular quiets cancer cells chatter

While braking tumor cancer cell growth of the University of Southern California researchers discovered new complex interrupt conversations.

Learn to read the full text of the press release.

###

Among the research institutions in NCI funding, all over the United States that current cancer specifies 68 as a Center. Based at research universities, these facilities are cancer's origin and development of intense laboratory research wide range, the scientists from NCI support many home. Cancer Center program is also focused on cross-cutting research, population Sciences, and clinical research please. Center for research results are often at the forefront of cancer research.

View the original article here